Dutasteride vs RU-58841
A side-by-side research comparison of Dutasteride and RU-58841 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dutasteride | RU-58841 |
|---|---|---|
| Full name | Dutasteride (Avodart) | RU-58841 (PSK-3841) |
| Category | Hair Growth | Hair Growth |
| Status | FDA Approved (BPH) / Off-label hair loss | Research compound |
| Mechanism | Inhibits both type I and type II 5-alpha reductase isoenzymes, reducing serum DHT by ~90% and scalp DHT by ~50%. Prevents miniaturization of androgen-sensitive hair follicles in the vertex and frontal scalp. | Non-steroidal androgen receptor antagonist with high binding affinity. Applied topically, penetrates to dermal papilla cells where it blocks DHT-AR complex formation, preventing transcription of hair-miniaturizing genes without systemic antiandrogen effects. |
| Molecular weight | 528.53 Da | 369.34 Da |
| Half-life | ~5 weeks (extremely long) | ~1 hour (in skin/plasma); active at receptor for 8-12h |
| Bioavailability | ~60% oral | Topical only - minimal systemic absorption |
| Typical dose | 0.5 mg | 50-100 mg in 1mL vehicle |
| Frequency | Daily | Daily application to scalp |
| Route | Oral capsule | Topical (dissolved in ethanol/PG vehicle) |
Dutasteride reported benefits
- Superior DHT suppression vs finasteride
- Hair regrowth and thickening
- Reduced hair miniaturization
- Prostate volume reduction
- Effective for diffuse thinning
RU-58841 reported benefits
- Local anti-androgen (no systemic effects)
- No sexual side effects
- DHT blocking at follicle level
- Can combine with oral finasteride
- Fast-acting (visible in weeks)
Related comparisons
Research and educational reference only. Not medical advice.